115 related articles for article (PubMed ID: 36736274)
1. Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity.
Orihara H; Ma M; Nagashima Y; Tochinai R; Sekizawa SI; Kato D; Shinada M; Aoki S; Fujita N; Nakagawa T; Tsuru Y; Tatewaki Y; Mutoh T; Taki Y; Nishimura R; Kuwahara M
Biomed Pharmacother; 2023 Apr; 160():114353. PubMed ID: 36736274
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats.
Nagashima Y; Tochinai R; Sekizawa SI; Kato D; Nakagawa T; Tsuru Y; Tatewaki Y; Mutoh T; Taki Y; Kuwahara M
J Toxicol Pathol; 2023 Jul; 36(3):151-158. PubMed ID: 37577366
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
4. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract][Full Text] [Related]
5. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
6. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
7. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
10. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 disodium phosphate-induced myocardial injury.
Tochinai R; Nagata Y; Ando M; Hata C; Suzuki T; Asakawa N; Yoshizawa K; Uchida K; Kado S; Kobayashi T; Kaneko K; Kuwahara M
J Toxicol Pathol; 2016 Jul; 29(3):163-71. PubMed ID: 27559241
[TBL] [Abstract][Full Text] [Related]
13. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
14. Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats.
Tochinai R; Komatsu K; Murakami J; Nagata Y; Ando M; Hata C; Suzuki T; Kado S; Kobayashi T; Kuwahara M
J Toxicol Pathol; 2018 Oct; 31(4):307-313. PubMed ID: 30393435
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
17. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
18. Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation.
Kong IY; Rimes JS; Light A; Todorovski I; Jones S; Morand E; Knight DA; Bergman YE; Hogg SJ; Falk H; Monahan BJ; Stupple PA; Street IP; Heinzel S; Bouillet P; Johnstone RW; Hodgkin PD; Vervoort SJ; Hawkins ED
Cell Rep; 2020 Oct; 33(3):108290. PubMed ID: 33086063
[TBL] [Abstract][Full Text] [Related]
19. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiother Oncol; 2001 Aug; 60(2):155-61. PubMed ID: 11439210
[TBL] [Abstract][Full Text] [Related]
20. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
